Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
Portfolio Pulse from Avi Kapoor
On CNBC's 'Halftime Report Final Trades,' analysts recommended Freeport-McMoRan, Pfizer, Danaher, and United Rentals. Freeport-McMoRan reported strong Q2 earnings and announced a $7.5 billion expansion. Pfizer received European approval for a gene therapy. Danaher and United Rentals also reported better-than-expected earnings.
July 26, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Danaher reported better-than-expected Q2 earnings with sales of $5.743 billion, despite a 3% year-over-year decrease.
Better-than-expected earnings are likely to positively impact Danaher's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Freeport-McMoRan reported Q2 revenue of $6.62 billion, beating estimates, and announced a $7.5 billion expansion of its El Abra copper mine.
Strong earnings and a significant expansion project are likely to positively impact Freeport-McMoRan's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Pfizer received European Commission approval for DURVEQTIX, a gene therapy for hemophilia B.
Regulatory approval for a new therapy is a positive development, likely boosting Pfizer's stock in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
United Rentals posted strong Q2 earnings and updated its 2024 revenue outlook to $15.05 billion-$15.35 billion.
Strong earnings and an improved revenue outlook are likely to positively impact United Rentals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100